ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2015
[Analysis of KIR3DL1 expression levels on 92 cases of normal donors for hematopoietic stem cells transplant].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- [Immune reconstruct regularity profile of KIR2DL1 and KIR3DL1 in unrelated-donor allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
- [Distribution of donor-specific aKIR after unrelated allogeneic hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study KIR3DL1 expression level on NK cell surface of normal donors for hematopoietic stem cell transplantation（HSCT）.
methodsNinety- two donors were performed by using of KIR genotyping, HLA high resolution genotyping and KIR3DL1 expression level using sequencebased testing（SBT）, PCR- sequence specific primer（SSP）and flow cytometry methods.
resultsIn 92 donors, the frequencies of KIR-A/A, Bx1, Bx2 for common genotypes were 46.74%（43/92）, 18.48% （17/92）and 9.78%（9/92）respectively（P<0.001）; KIR-A, B1, B2, B3 for common KIR haplo-type were 70.33%（128/182）, 10.99%（20/182）, 7.14%（13/182） and 4.39%（8/182） respectively（P<0.001）; the frequencies of HLA-BW4/BW4, HLA-BW4/BW6, BW6/BW6 ligands were 13.79%, 67.81% and 18.39% respectively（P<0.001）. KIR3DL1 middle expression level among haplo- type KIR- A/A and KIR- Bx, KIR-B/B were 18.77%（3.11%-49.24%）, 13.14%（1.70%-63.32%）and 0.37%（0.20%-2.60%）respectively （P<0.05）. KIR3DL1 expression level［18.77%（3.11%-49.24%）］in haplo-type KIR-A/A was higher than haplo-type KIR-Bx at the same time did not express 2DL2 group［11.20%（3.50%-36.08%）］（P=0.019）. KIR3DL1 expression level in recognition group（HLA-BW4 positive group）［17.61%（1.40%-49.24%）］ was higher than KIR3DL1 unrecognized group（HLA-BW4 negative group）［10.60%（3.50%-18.56%）］ （P=0.006）.
conclusionThe expression levels of KIR3DL1 in different KIR genotypes, haplotypes and HLA ligands were statistically significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.